Abstract:Objective: To prospectively observe the long-term antiviral efficacy and safety of telbivudine (LDT) administered as a monotherapy and as a combination therapy with adefovir dipivoxil (ADV) in patients diagnosed with chronic hepatitis B (CHB) and positivity for hepatitis B e antigen (HBeAg). Methods: A total of 140 patients with HBeAg-positive CHB were randomly divided into treatment groups for LDT monotherapy (n = 75; 600 mg orally, once daily) and LDT+ADV combination therapy (n = 65; LDT 600 mg plus ADV 10 mg orally, once daily). The shortest treatment course was 96 weeks and the longest was 240 weeks. At treatment weeks 12, 24, 48?, 96, 144, 192, and 240 patients were tested for hepatitis B virus (HBV) DNA, HBeAg seroconversion and ALT normalization time; in addition, the incidence and type of adverse drug reactions were recorded. Data were statistically analyzed to determine the significance of differences observed between groups. Results: The rate of patients experiencing more than or equal to 2 log HBV DNA reduction was higher in the LDT + ADV group (92.3%(60/65) vs. LDT: 86.7%(65/75), X2 = 1.58). The HBV DNA negative rates of the LDT and LDT + ADV groups were 62.7% and 61.5% (X2 = 0.01) at week 24, 76.0% and 81.5% (X2 = 0.63) at week 48, 80.0% and 89.2% (X2 = 2.2) at week 96, 78.3% and 93.3% (X2 = 3.24) at week 144, 83.7% and 91.7% (X2 = 0.47) at week 192, and 93.3% and 88.9% at week 240 (comparison between two groups for each point P more than 0.05); both groups showed higher early and rapid sustained HBV DNA negative rates. For the HBeAg seroconversion, the rates of the LDT and LDT + ADV groups were 17.3% and 23.1% (X2 = 0.71) at week 24, 29.3% and 30.8% (X2 = 0.03) at week 48, 42.7% and 40.0% (X2 = 0.10) at week 96, 55.0% and 43.3% (X2 = 1.08) at week 144, 55.8% and 66.7% (X2 = 0.45) at week 192, and 63.3% and 66.7% at week 240; however, pairwise comparison showed no statistically significant differences between the groups (P more than 0.05). Similarly, there was no significant difference between the two groups in incidence of resistance at week 48 (4.0% and 1.5%), week 96 (5.3% and 3.1%), week 144 (10.0% and 3.3%, X2 = 1.23), week 192 (11.6% and 8.3%), and week 240 (13.3% and 11.1%) (all P more than 0.05). Three patients experienced muscle soreness (LDT, n = 2; LDT + ADV, n = 1) and two patients experienced increased creatine phosphokinase (LDT, n = 1; LDT + ADV, n = 1); all side effects resolved spontaneously or with symptom-appropriate treatment. Conclusion: The long-term efficacy of LDT as a monotherapy or as a combination therapy with ADV was similar and the two different treatment approaches were associated with similar rates of resistance. The long-term safety was good for both treatment approaches.

Determination of Telbivudine in the Plasma of Chronic Hepatitis B Patients in Long-Term Treatment by High-Performance Liquid Chromatographic-Tandem Mass Spectrometry.

P414 ASSESSMENT OF THE CHANGE IN ESTIMATED GLOMERULAR FILTRATION RATES IN TELBIVUDINE- OR LAMIVUDINE-BASED TRERAPY IN PATIENTS WITH CHRONIC HEPATITIS B

Effect of Telbivudine Therapy on the Cellular Immune Response in Chronic Hepatitis B

Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.

Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4

Chronic Hepatitis B: A Critical Discussion

Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B.

[Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients]

Cumulative Incidence and Risk Factors of Creatine Kinase Elevation Associated with Telbivudine

Clinical Trail of Decoction of Tonifying Qi Activating Blood and Detoxifcation in the Treatment of Chronic Hepatitis B Patients with Alanine Aminotransferase Less than Two-time upper Limits of Normal Level

Predictive Value of Serum ALT and T-cell Receptor Beta Variable Chain for HBeAg Seroconversion in Chronic Hepatitis B Patients During Tenofovir Treatment

The efficacy of telbivudi ne treatment in patients with HBeAg-positive hepatitis B

Plasma Level of ADAMTS13 or IL-12 As an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing M-Etv Treatment

Potential Effects of Telbivudine Versus Entecavir on Renal Function in Patients with Chronic Hepatitis B Virus Receiving Glucocorticoids Therapy.

The Ca2+/CaMKK2 Axis Mediates the Telbivudine Induced Upregulation of Creatine Kinase: Implications for Mechanism of Antiviral Nucleoside Analogs' Side Effect.

Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B.

Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir

910 A PROSPECTIVE, RANDOMIZED STUDY OF EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A VERSUS ADEFOVIR DIPIVOXIL IN TREATING LAMIVUDINE- RESISTANT HBeAg-POSITIVE CHB

A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China

Effects of Telbivudine and Lamivudine on Hepatitis B Serum Antigen in Patients with Chronic Hepatitis B

Early prediction of efficacy of telbivudine in the treatment of patients with HBeAg-positive chronic hepatitis B